# South America Onychomycosis Market

> South America Onychomycosis Market Research Report By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candida Onychomycosis, Others), By Treatment Type (Drug Treatment, Topical Therapy, Others), By End Users (Hospital Pharmacies, Retail Pharmacies, Others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.2%
- **2024:** $ 417 Million
- **2025:** $ 438.68 Million
- **2035:** $ 728.45 Million
- **Key Players:** Bayer AG (DE), Novartis AG (CH), Johnson & Johnson (US), GlaxoSmithKline plc (GB), Pfizer Inc. (US), Sanofi S.A. (FR), Merck & Co., Inc. (US), AbbVie Inc. (US), Astellas Pharma Inc. (JP)

**Report ID:** MRFR/HC/55187-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-onychomycosis-market-56953

---

## Market Summary

## **South America Onychomycosis Market Overview**

As per MRFR analysis, the South America Onychomycosis Market Size was estimated at 398 (USD Million) in 2023. The South America Onychomycosis Market Industry is expected to grow from 417(USD Million) in 2024 to 706.7 (USD Million) by 2035. The South America Onychomycosis Market CAGR (growth rate) is expected to be around 4.912% during the forecast period (2025 - 2035)

**Key South America Onychomycosis Market Trends Highlighted**

In the South America Onychomycosis Market, key market drivers include the increasing prevalence of fungal infections and rising awareness about foot health among the population. The region experiences favorable climatic conditions that contribute to the spread of these infections, especially in humid areas like the Amazon basin. Additionally, the growing geriatric population is more susceptible to onychomycosis, further driving market growth. Opportunities to be explored include the development of affordable and effective antifungal treatments that cater to different demographic needs. Local pharmaceutical companies are focusing on creating specialized medications aimed at treating fungal nail infections, reflecting an untapped market potential.

In South America, there has been a distinct movement toward innovative diagnostic applications and telemedicine practices. Technology is making it possible to obtain treatment and improve patient results. Health authority educational campaigns are improving knowledge about onychomycosis's persistent issue and its prevalent treatment ways, thus increasing the demand for therapy region-wide. Furthermore, the shift towards natural and organic products is also gaining attention as it's safer and less toxic instead of being used on children.

The use of standard treatment guidelines is encouraged by the region’s governing bodies, which might assist in meeting the regional health demands through the acquisition of new products and their enhanced treatment efficaciousness.

As a result, these trends signal a growing interest in innovative and effective solutions for onychomycosis treatment in South America, paving the way for substantial industry advancements.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South America Onychomycosis Market Drivers**

**Rising Incidence of Onychomycosis in South America**

The South America Onychomycosis Market Industry is experiencing significant growth due to the increasing incidence of onychomycosis, a fungal infection affecting the nails. Recent health reports indicate that dermatological issues, including fungal infections, are on the rise in various South American countries. For instance, Brazil's National Health System has noted a 40% increase in cases of dermatophytic infections, including onychomycosis, over the last decade.As public health agencies and dermatology associations work to address the prevalence of these infections, the demand for effective treatment options is expected to grow. 

Institutes like the Brazilian Society of Dermatology actively promote awareness and provide treatment guidelines, thereby fostering growth in the South America Onychomycosis Market. The escalating rate of onychomycosis treatments and products, such as topical antifungals and laser therapies, further solidifies the market's potential in South America, thereby projecting considerable revenue growth in the coming years.

**Increased Awareness and Diagnosis of Fungal Infections**

The South America Onychomycosis Market Industry is also being driven by heightened awareness and improved diagnosis of fungal infections. Initiatives led by organizations such as the Brazilian Ministry of Health have focused on infectious diseases improving education regarding dermatological conditions. Recently, the agency reported that public awareness campaigns have increased dermatological visits by 25% in urban centers. 

With better diagnostic tools and training for healthcare professionals, the rate of diagnosed cases of onychomycosis is set to rise.As more patients seek treatment and education is enhanced, manufacturers can anticipate an uptick in demand for onychomycosis treatment products and services in the South America Onychomycosis Market, contributing to its overall growth.

**Aging Population in South America**

The demographic shift towards an aging population in South America plays a crucial role in the growth of the South America Onychomycosis Market Industry. According to the Economic Commission for Latin America and the Caribbean, the percentage of individuals over 60 years old is projected to rise significantly, from 10% currently to 20% by 2030. This age group is more susceptible to various health issues, including onychomycosis, due to weakened immunity and other health-related factors.

As elder care and geriatric healthcare become more prioritized in policies across South American nations, there will be an inherent increase in the focus on treating onychomycosis among older adults. Consequently, this demographic trend is expected to lead to greater market opportunities for suppliers of onychomycosis treatments in the region.

**South America Onychomycosis Market Segment Insights**

**Onychomycosis Market Type Insights**

The South America Onychomycosis Market is primarily segmented by type, focusing on various forms of nail fungal infections that are prevalent in the region. Distal Subungual Onychomycosis stands out as a significant type, characterized by its higher incidence and more challenging treatment options, which exacerbates its clinical importance in South America. White Superficial Onychomycosis, while less common, garners attention due to its visible nature that can prompt earlier diagnosis and treatment among individuals. Additionally, Proximal Subungual Onychomycosis, often associated with immunocompromised patients, raises awareness of the link between systemic health issues and nail infections.

Candida Onychomycosis also plays a critical role, particularly in tropical areas of South America, where higher humidity can facilitate fungal growth, making it an important area for treatment and market development. The category of "Others" captures various less common fungal infections that still contribute to the overall burden of onychomycosis in this region. Overall, the landscape of the South America Onychomycosis Market segmentation by type highlights the diverse challenges presented by different fungal infections, driving the need for tailored treatment approaches and fostering growth opportunities for pharmaceutical companies focused on this niche yet significant market.

As public awareness of skin health rises in South America, the demand for effective treatments will likely continue to grow, presenting both opportunities and challenges for stakeholders within the South America Onychomycosis Market. Furthermore, significant public health campaigns aimed at educating the population about fungal infections and promoting early treatment could enhance engagement in addressing this prevalent condition across the region.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Onychomycosis Market Treatment Type Insights**

The Treatment Type segment of the South America Onychomycosis Market encompasses various methods aimed at effectively tackling fungal nail infections. This segment includes Drug Treatment, Topical Therapy, and other treatment options, all of which play critical roles in addressing this common condition. Drug Treatment is crucial as it often provides systemic solutions, making it effective for more severe infections that do not respond to surface therapies. Topical Therapy, on the other hand, remains significant due to its non-invasive nature and convenience for patients, making it a preferred choice for mild cases.

Other therapies include oral medications and potential new methodologies, which are gaining traction as advances in treatment options proliferate. The rising awareness of foot health and increasing incidences of nail fungi in humid climates prevalent in South America are contributing factors to the market's expansion. Overall, the increasing focus on effective and accessible treatment options is expected to shape the dynamics within the South America Onychomycosis Market, driving satisfactory outcomes for both patients and healthcare providers alike.

**Onychomycosis Market End Users Insights**

The South America Onychomycosis Market showcases diverse End Users that play crucial roles in the distribution and accessibility of treatments. Hospital pharmacies have emerged as vital players due to their capability to provide tailored medical solutions and a broader range of antifungal formulations, thereby enhancing patient outcomes. Retail pharmacies possess a significant presence in the market, offering convenient access to over-the-counter products and increasing awareness of onychomycosis among the general public, which drives product demand.

The Others segment, encompassing online pharmacies and alternative health outlets, taps into the growing trend of digital healthcare, reflecting shifts in consumer behavior towards online purchasing and consultation. This diversity within the End Users highlights the variable pathways through which patients access treatments, influenced by factors such as convenience, medical advice, and cultural attitudes toward healthcare in South America.

Overall, the segmentation among End Users contributes to the market growth by ensuring that treatments are available in various formats and settings, aligning with regional healthcare challenges and consumer preferences.The trends within these segments suggest an ongoing evolution in response to the growing prevalence of onychomycosis and increasing awareness in South America, ultimately influencing the South America Onychomycosis Market data significantly.

**Onychomycosis Market Regional Insights**

The South America Onychomycosis Market is characterized by its diverse regional segmentation, primarily including Brazil, Mexico, Argentina, and the Rest of South America. Brazil holds a substantial share of the market due to its large population and rising awareness about fungal infections that affect nail health. Mexico follows, with a significant market contribution fueled by an increasing incidence rate of onychomycosis along with a growing focus on personal health and hygiene.

Argentina also plays a notable role in the market, driven by a rising healthcare infrastructure and access to better treatment options.The Rest of South America includes various countries where awareness and treatment options are gradually improving, contributing to overall market growth. 

The collective demand for antifungal treatments and supportive healthcare services in these regions indicates a promising future for the South America Onychomycosis Market, propelled by increasing population health consciousness and ongoing healthcare advancements. Additionally, regional healthcare initiatives and investment in dermatological therapies present further opportunities for market expansion across South America.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South America Onychomycosis Market Key Players and Competitive Insights****:**

The South America Onychomycosis Market has been witnessing significant growth attributed to the rising prevalence of fungal nail infections, increasing awareness among the population about the disease, and an expanding range of treatment options available in the region. The competitive landscape is characterized by a mix of global and regional players vying for market share through innovative product offerings and robust marketing strategies. The competition is intensified further due to the evolving regulatory landscape, which encourages companies to develop effective and safe therapeutic solutions. 

As the market matures, focus on advanced drug formulations and delivery systems becomes paramount, leading to increased investments and research and development efforts. Amgen has established a notable presence in the South America Onychomycosis Market through its innovative product portfolio and extensive distribution networks. The company is recognized for its commitment to research in fungal infections and its ability to offer effective treatment options tailored toward patient needs. 

One of the key strengths of Amgen lies in its well-established reputation for high-quality pharmaceutical products, along with its strong relationships with healthcare professionals that enhance its market positioning. Their strategic marketing approaches and localized training programs for medical representatives further ensure that the onychomycosis treatment options are well-promoted and accessible across various regions in South America. GSK plays a significant role in the South America Onychomycosis Market, providing a comprehensive range of antifungal medications that cater to diverse patient demographics.

The strength of GSK’s market presence is bolstered by its well-researched product pipeline and focus on patient compliance, leading to effective outcomes in onychomycosis treatment. 

GSK has also pursued strategic mergers and acquisitions in the region to enhance its portfolio and distribution capabilities, which has markedly improved its reach in South America. Among its key products, GSK focuses on topical treatments and systemic therapies aimed at addressing the specific needs of patients suffering from fungal infections. The company’s strong emphasis on community engagement and collaboration with local healthcare providers ensures that its products are effectively integrated into treatment regimes, further solidifying its competitive advantage in the market.

**Key Companies in the South America Onychomycosis Market Include**

- Amgen
- GSK
- Bayer
- Galderma
- AbbVie
- Teva
- Eli Lilly
- Astellas
- Merck
- Sanofi
- Incyte
- Novartis
- Johnson & Johnson
- Pfizer

**South America Onychomycosis Market Industry Developments**

The South America Onychomycosis Market has seen several developments recently. In October 2023, Amgen received approval for a new topical treatment specifically targeting onychomycosis, which is expected to enhance its market presence. Additionally, GSK launched a public awareness campaign across Brazil, aiming to educate patients about fungal nail infections and the importance of seeking treatment. In July 2023, Bayer and Galderma announced an agreement to collaborate on joint clinical trials, combining their efforts to advance therapy options for onychomycosis, showcasing a commitment to Research and Development in this field. 

The market has experienced valuation growth, driven by rising awareness and demand for effective treatments, specifically in urban areas of South America. Moreover, in January 2022, AbbVie expanded its product line for dermatological conditions in Argentina, further indicating the increasing focus on addressing fungal infections, including onychomycosis. The competitive landscape remains robust, with strong efforts from Merck and Pfizer to introduce innovative therapies. Overall, market dynamics depict a trend towards enhanced treatment availability, fueled by ongoing Research and Development and collaborative initiatives among key players.

**South America Onychomycosis Market Segmentation Insights**

**Onychomycosis Market Type****Outlook**

- Distal Subungual Onychomycosis
- White Superficial Onychomycosis
- Proximal Subungual Onychomycosis
- Candida Onychomycosis
- Others

**Onychomycosis Market Treatment Type****Outlook**

- Drug Treatment
- Topical Therapy
- Others

**Onychomycosis Market End Users****Outlook**

- Hospital Pharmacies
- Retail Pharmacies
- Others

**Onychomycosis Market Regional****Outlook**

- Brazil
- Mexico
- Argentina
- Rest of South America

## Market Drivers

### Growing Geriatric Population

The growing geriatric population in South America is a significant driver for the onychomycosis market. Older adults are more susceptible to fungal infections due to weakened immune systems and other comorbidities. As the population aged 65 and above continues to increase, the prevalence of onychomycosis is likely to rise correspondingly. This demographic shift suggests a potential market expansion, with estimates indicating that the geriatric segment could account for over 50% of onychomycosis cases. Consequently, pharmaceutical companies are likely to focus on developing age-appropriate formulations and treatment regimens to cater to this vulnerable population.

### Rising Healthcare Expenditure

Rising healthcare expenditure in South America is positively impacting the onychomycosis market. As governments and private sectors invest more in healthcare infrastructure, access to medical services and treatments improves. Increased spending on healthcare is likely to lead to higher awareness and diagnosis rates of onychomycosis, resulting in greater demand for effective treatment options. Reports suggest that healthcare spending in some South American countries has increased by approximately 8-10% annually. This trend may facilitate the introduction of new therapies and medications, thereby enhancing the overall market landscape for onychomycosis treatments.

### Emergence of E-commerce Platforms

The emergence of e-commerce platforms is transforming the distribution landscape of the onychomycosis market in South America. With the rise of online shopping, consumers are increasingly turning to digital platforms for purchasing medications and treatments. This shift not only enhances accessibility but also allows for competitive pricing and a wider range of product options. E-commerce sales in the pharmaceutical sector have been growing at an estimated rate of 15-20% annually. As more consumers opt for online purchases, the onychomycosis market is likely to benefit from increased sales and market penetration, particularly in regions with limited access to traditional pharmacies.

### Advancements in Diagnostic Techniques

Advancements in diagnostic techniques for onychomycosis are significantly influencing the onychomycosis market in South America. Improved diagnostic methods, such as molecular testing and dermatoscopy, allow for quicker and more accurate identification of fungal infections. This not only enhances patient outcomes but also encourages healthcare providers to initiate treatment sooner. As a result, the demand for effective antifungal treatments is expected to rise. The market could see a growth rate of approximately 5-7% annually as these diagnostic innovations become more widely adopted in clinical practice, thereby driving the overall market for onychomycosis treatments.

### Increasing Incidence of Onychomycosis

The rising incidence of onychomycosis in South America is a critical driver for the onychomycosis market. Factors such as humid climates and increased exposure to fungal infections contribute to this trend. Recent studies indicate that the prevalence of onychomycosis in certain South American countries may reach as high as 10-15% of the population. This growing incidence necessitates effective treatment options, thereby propelling the demand for antifungal medications and therapies. As more individuals seek treatment, the onychomycosis market is likely to expand, with pharmaceutical companies focusing on developing targeted therapies to address this increasing health concern.

## Future Outlook

The [Onychomycosis Market](https://www.marketresearchfuture.com/reports/onychomycosis-market-1340) is projected to grow at a 5.2% CAGR from 2025 to 2035, driven by increasing awareness, innovative treatments, and rising healthcare expenditure.

**New opportunities:**

- Development of telehealth platforms for remote consultations and prescriptions.
- Investment in R&D for novel antifungal agents targeting resistant strains.
- Expansion of over-the-counter treatment options in retail pharmacies.

By 2035, the market is expected to achieve substantial growth, driven by innovation and increased accessibility.

## Segment Insights

### By Type: Distal Subungual Onychomycosis (Largest) vs. Candida Onychomycosis (Fastest-Growing)

In the South America onychomycosis market, Distal Subungual Onychomycosis (DSO) commands the largest share, attributed to its prevalence compared to other types. Following closely are White Superficial Onychomycosis (WSO) and Candida Onychomycosis, which reflect growing interest due to increasing awareness and diagnosis. Proximal Subungual Onychomycosis (PSO) and Others occupy smaller market segments, highlighting the specific nature of fungal infections in this geographical region. The growth trends within this segment indicate a rising demand for treatments targeting DSO, driven by an increase in healthcare access and the prevalence of risk factors such as diabetes and immunocompromised states among the population. Candida Onychomycosis is emerging rapidly, benefiting from advancements in antifungal therapies and growing research, promising enhanced patient outcomes and broadening its market presence within South America.

Distal Subungual Onychomycosis (Dominant) vs. Candida Onychomycosis (Emerging)

Distal Subungual Onychomycosis (DSO) remains the dominant type in the South America onychomycosis market, accounting for a significant share due to its commonality in fungal nail infections. This dominance is supported by extensive clinical awareness and established treatment protocols. In contrast, Candida Onychomycosis is considered an emerging player, experiencing rapid growth as awareness increases among healthcare providers and patients. It presents unique treatment challenges, which have led to ongoing developments in antifungal medications and therapies, thereby increasing its footprint in the market. The differentiation in patient demographics and treatment approaches reinforces the significance of both segments in understanding the onychomycosis landscape in South America.

### By Treatment Type: Topical Therapy (Largest) vs. Drug Treatment (Fastest-Growing)

In the South America onychomycosis market, the treatment type segment reveals a diverse landscape with Topical Therapy holding the largest share. This preference is driven by ease of use and effectiveness, appealing to a broad demographic seeking accessible treatment options. Conversely, Drug Treatment, comprising systemic therapies, is emerging as the fastest-growing segment due to an increasing awareness of onychomycosis and the effectiveness of newer oral medications in severe cases. The growth trends in the treatment type segment are significantly influenced by factors like rising patient awareness, increasing incidence of skin diseases, and the introduction of innovative treatment options. The availability of over-the-counter topical therapies enhances accessibility for consumers, while the growing emphasis on comprehensive care encourages more patients to seek systemic drug treatments. This dynamic interplay between the segments underscores a shift towards more effective treatment protocols in the region.

Topical Therapy: Dominant vs. Drug Treatment: Emerging

Topical Therapy is characterized by its broad acceptance and dominance in the market, mainly due to its non-invasive nature and ease of application. This segment caters to a wide range of patients, including those preferring self-treatment options. Its efficacy in treating mild to moderate cases of onychomycosis solidifies its status as the dominant treatment. On the other hand, Drug Treatment is categorized as an emerging segment, gaining traction as awareness of severe cases grows. With advancements in pharmaceutical formulations, such as oral antifungal agents, the segment is positioned for accelerated growth, appealing to patients requiring more robust interventions. This dichotomy illustrates the evolving preferences and adoption of treatment modalities in response to the specific needs of patients in the region.

### By End User: Hospital Pharmacies (Largest) vs. Retail Pharmacies (Fastest-Growing)

The market share distribution among the end user segments reveals that hospital pharmacies dominate the landscape, holding a significant portion of the market aimed at providing specialized treatments. In contrast, retail pharmacies are quickly gaining ground, appealing to everyday consumers seeking accessible treatment options for onychomycosis, which contributes to a shift in market dynamics. Others, while present, represent a smaller slice of the market, indicating a concentrated focus on these primary outlets. Growth trends indicate a robust increase in the retail pharmacy segment, driven by rising awareness of onychomycosis and the convenience factor for consumers. Hospital pharmacies continue to thrive, fueled by their established relationships with healthcare providers and specialized care. Sociocultural factors, including an increasing emphasis on self-treatment and accessibility, are propelling the retail segment forward, shaping a dynamic and competitive market landscape.

Hospital Pharmacies (Dominant) vs. Retail Pharmacies (Emerging)

Hospital pharmacies are characterized by their strong focus on comprehensive patient care, offering specialized medications and treatments for onychomycosis. Their dominance in the market is attributed to the established trust they maintain with healthcare professionals and patients alike. They typically provide access to more potent treatments that may not be available in retail settings. On the other hand, retail pharmacies are fast emerging as key players in this sector, leveraging their accessibility and convenience to attract consumers. They are increasingly expanding their product offerings, introducing over-the-counter treatments, and engaging in marketing strategies that raise awareness, thus enhancing consumer trust and demand. This dual structure in the market not only highlights varied consumer preferences but also drives innovation and competitiveness.

## Regional Market Share Analysis

### Brazil : Leading Market Share and Growth Drivers

Brazil holds a commanding market share of 45% in the South American onychomycosis market, valued at $180.0 million. Key growth drivers include increasing awareness of fungal infections, rising disposable incomes, and a growing elderly population. Demand trends indicate a shift towards topical treatments, supported by government initiatives promoting healthcare access. Regulatory policies are becoming more favorable, with streamlined approval processes for antifungal medications, enhancing market dynamics. Infrastructure improvements in healthcare facilities further bolster industrial development in this sector. Key cities such as São Paulo and Rio de Janeiro are pivotal markets, showcasing a competitive landscape dominated by major players like Bayer AG and Johnson & Johnson. The presence of local manufacturers also intensifies competition, fostering innovation in treatment options. The business environment is characterized by a mix of established pharmaceutical companies and emerging startups, focusing on both prescription and over-the-counter products. The dermatological sector is particularly active, with a growing emphasis on preventive care and patient education.

### Mexico : Increasing Demand for Antifungal Treatments

Mexico accounts for 22.5% of the South American onychomycosis market, valued at $90.0 million. The market is driven by a rising prevalence of fungal infections, particularly in urban areas, and increasing healthcare expenditure. Demand for effective antifungal treatments is on the rise, supported by government health campaigns aimed at educating the public about onychomycosis. Regulatory frameworks are evolving, with efforts to expedite the approval of new treatments, enhancing market accessibility. Infrastructure improvements in healthcare facilities are also contributing to market growth. Key markets include Mexico City and Guadalajara, where the competitive landscape features significant players like Novartis AG and Pfizer Inc. The presence of local distributors and pharmacies enhances product availability, while the business environment is becoming increasingly favorable for new entrants. The dermatology sector is witnessing innovation, with a focus on developing combination therapies and patient-centric solutions to improve treatment adherence and outcomes.

### Argentina : Regulatory Support and Market Dynamics

Argentina holds a market share of 17.5%, valued at $70.0 million in the onychomycosis sector. Key growth drivers include an increasing awareness of fungal infections and a rise in healthcare spending. Demand trends show a preference for topical treatments, supported by government initiatives aimed at improving public health. Regulatory policies are becoming more supportive, with streamlined processes for drug approvals, which is crucial for market expansion. The development of healthcare infrastructure is also enhancing access to treatments across the country. Buenos Aires and Córdoba are key markets, with a competitive landscape featuring major players like GlaxoSmithKline plc and Merck & Co., Inc. The local market dynamics are characterized by a mix of international and domestic companies, fostering a competitive environment. The business climate is improving, with a focus on innovative treatment options and patient education initiatives. The dermatological sector is particularly active, with increasing collaboration between healthcare providers and pharmaceutical companies to enhance treatment accessibility.

### Rest of South America : Varied Demand Across Sub-regions

The Rest of South America represents a market share of 19.25%, valued at $77.0 million in the onychomycosis market. Key growth drivers include rising awareness of fungal infections and increasing healthcare access in countries like Chile and Colombia. Demand trends indicate a growing preference for both prescription and over-the-counter treatments, supported by government health initiatives. Regulatory policies vary by country, with some regions experiencing faster approval processes for antifungal medications, which is crucial for market growth. Infrastructure development is uneven, impacting market dynamics across the region. Key markets include Santiago and Bogotá, where the competitive landscape features a mix of local and international players, including AbbVie Inc. and Astellas Pharma Inc. The business environment is diverse, with varying levels of market maturity and regulatory support. The dermatology sector is evolving, with a focus on improving treatment options and patient access, driven by local healthcare policies and initiatives aimed at combating fungal infections.

## Competitive Benchmarking

The [onychomycosis market](https://www.marketresearchfuture.com/reports/onychomycosis-market-1340) exhibits a competitive landscape characterized by a blend of established pharmaceutical giants and emerging players, driven by increasing awareness of fungal infections and the growing demand for effective treatment options. Key players such as Bayer AG (Germany), Novartis AG (Switzerland), and Johnson & Johnson (US) are strategically positioned to leverage their extensive research capabilities and established distribution networks. Bayer AG (Germany) focuses on innovation in antifungal therapies, while Novartis AG (Switzerland) emphasizes partnerships to enhance its product portfolio. Johnson & Johnson (US) is actively pursuing digital transformation initiatives to improve patient engagement and treatment adherence, collectively shaping a dynamic competitive environment.
The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production to reduce costs and enhance responsiveness to regional demands. This strategy not only streamlines operations but also fosters a more agile market presence, allowing firms to adapt to the unique needs of South American consumers. The collective influence of these key players contributes to a competitive atmosphere where innovation and operational efficiency are paramount.
In August 2025, Bayer AG (Germany) announced the launch of a new topical antifungal treatment specifically designed for onychomycosis, which is expected to enhance patient compliance due to its ease of application. This strategic move underscores Bayer's commitment to addressing unmet medical needs and positions the company favorably against competitors. The introduction of this product may potentially capture a significant share of the market, particularly among patients seeking effective and user-friendly treatment options.
In September 2025, Novartis AG (Switzerland) entered into a strategic partnership with a local biotechnology firm to co-develop a novel oral antifungal agent targeting onychomycosis. This collaboration not only expands Novartis's research capabilities but also enhances its market reach in South America. The partnership reflects a growing trend among pharmaceutical companies to leverage local expertise and resources, which could lead to more tailored solutions for regional patients.
In October 2025, Johnson & Johnson (US) unveiled a digital health platform aimed at improving the management of onychomycosis through telemedicine consultations and personalized treatment plans. This initiative highlights the increasing importance of digitalization in healthcare, particularly in enhancing patient access to care. By integrating technology into its service offerings, Johnson & Johnson is likely to strengthen its competitive position and foster greater patient loyalty.
As of November 2025, the competitive trends in the onychomycosis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming more prevalent, enabling companies to pool resources and expertise to drive innovation. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to deliver innovative solutions that meet evolving patient needs.

## Recent News & Developments

The South America Onychomycosis Market has seen several developments recently. In October 2023, Amgen received approval for a new topical treatment specifically targeting onychomycosis, which is expected to enhance its market presence. Additionally, GSK launched a public awareness campaign across Brazil, aiming to educate patients about fungal nail infections and the importance of seeking treatment. In July 2023, Bayer and Galderma announced an agreement to collaborate on joint clinical trials, combining their efforts to advance therapy options for onychomycosis, showcasing a commitment to Research and Development in this field. 

The market has experienced valuation growth, driven by rising awareness and demand for effective treatments, specifically in urban areas of South America. Moreover, in January 2022, AbbVie expanded its product line for dermatological conditions in Argentina, further indicating the increasing focus on addressing fungal infections, including onychomycosis. The competitive landscape remains robust, with strong efforts from Merck and Pfizer to introduce innovative therapies. Overall, market dynamics depict a trend towards enhanced treatment availability, fueled by ongoing Research and Development and collaborative initiatives among key players.

## Report Scope

| MARKET SIZE 2024 | 417.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 438.68(USD Million) |
| MARKET SIZE 2035 | 728.45(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Bayer AG (DE), Novartis AG (CH), Johnson & Johnson (US), GlaxoSmithKline plc (GB), Pfizer Inc. (US), Sanofi S.A. (FR), Merck & Co., Inc. (US), AbbVie Inc. (US), Astellas Pharma Inc. (JP) |
| Segments Covered | Type, Treatment Type, End User |
| Key Market Opportunities | Emerging antifungal therapies and telehealth solutions enhance access in the onychomycosis market. |
| Key Market Dynamics | Rising demand for effective antifungal treatments drives innovation and competition in the onychomycosis market. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What is the current valuation of the South America onychomycosis market in 2024?**
A: The market valuation was $417.0 Million in 2024.

**Q: What is the projected market size for the South America onychomycosis market by 2035?**
A: The projected market size is $728.45 Million by 2035.

**Q: What is the expected CAGR for the South America onychomycosis market during the forecast period 2025 - 2035?**
A: The expected CAGR is 5.2% during the forecast period 2025 - 2035.

**Q: Which segment had the highest valuation in the South America onychomycosis market in 2024?**
A: The 'Others' segment had the highest valuation at $157.0 Million in 2024.

**Q: What are the key treatment types in the South America onychomycosis market?**
A: Key treatment types include Drug Treatment, Topical Therapy, and Others.

**Q: How much did the Drug Treatment segment generate in 2024?**
A: The Drug Treatment segment generated $200.0 Million in 2024.

**Q: Which companies are leading the South America onychomycosis market?**
A: Key players include Bayer AG, Novartis AG, Johnson & Johnson, and others.

**Q: What is the valuation range for the Distal Subungual Onychomycosis segment in 2024?**
A: The valuation range for Distal Subungual Onychomycosis was $100.0 Million to $180.0 Million in 2024.

**Q: What is the expected growth trend for the South America onychomycosis market?**
A: The market is expected to grow steadily, reaching $728.45 Million by 2035.

**Q: What was the valuation of Retail Pharmacies in the South America onychomycosis market in 2024?**
A: Retail Pharmacies had a valuation of $200.0 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-onychomycosis-market-56953*